NINDS Neuroscience Funding Announcements

Funding Resources
Funding Overview
Funding Strategy

Funding Opportunities

Grant Mechanisms
Training & Career
Development
Contracts Management
Review Committees
Funding News
Program Areas

Research
Anticonvulsant Screening
   Program
Clinical Research
Counterterrorism
Epilepsy Research Web
Neural Interfaces Program
NIH Roadmap Research
Parkinson's Web
Resources for Scientists
Stem Cell Research
Translational Research
Traumatic Brain Injury
   (TBI) Research
Technology Transfer
   Office

NINDS is part of the
National Institutes of
Health

Download Adobe Reader

Print-friendly version

Email this page

Application processes at NIH are changing. Applicant organizations are encouraged to start preparing for this transition by registering with Grants.gov and NIH eRA Commons now.

Hyperaccelerated Award/Mechanisms in Immunomodulation Trials
Release Date: November 24, 1999
Announcement Number: RFA-AI-00-005
Application Receipt Date:
May 9, 2002
Letter of Intent Date: April 9, 2002

Funding Contact: NINDS Funding
Program Area: Neural Environment

Brief Description:
The National Institute of Allergy and Infectious Diseases (NIAID), the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the National Heart, Lung and Blood Institute (NHLBI), the National Institute of Neurological Disorders and Stroke (NINDS), and the Office of Research on Women’s Health (ORWH) of the National Institutes of Health (NIH) invite investigator-initiated research applications for mechanistic studies in clinical trials of immunomodulatory interventions for immune system mediated diseases, including, but not limited to, asthma and allergy, graft failure in solid organ, tissue, cell and stem cell transplantation, and autoimmune diseases. Specifically, this Request for Applications (RFA) is a continuation and modification of RFA AI-98-006. It focuses on the inclusion of patients and utilization of patient samples for the evaluation of immunologic and other relevant parameters to facilitate the study and definition of immunological mechanisms underlying the intervention, the mechanisms of disease pathogenesis, surrogate/biomarkers markers of disease activity and therapeutic effect, and mechanisms of human immunologic function. The parent or core clinical trial must have independent financial support and will NOT receive support under this RFA. Proposed mechanistic studies associated with clinical trials supported by industry are particularly encouraged but clinical trials supported by any source, public or private, are eligible.

Choose an option to view additional funding announcements